Literature DB >> 27011373

68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging.

Thorsten Derlin1, Desiree Weiberg2, Christoph von Klot3, Hans-Jürgen Wester4, Christoph Henkenberens5, Tobias L Ross2, Hans Christiansen5, Axel S Merseburger6, Frank M Bengel2.   

Abstract

OBJECTIVE: Urinary radiotracer excretion of 68Ga-Labelled prostate-specific membrane antigen (PSMA) ligands may complicate the assessment of the prostate region and differentiation of lymph nodes from ureteral activity. The aim of this study was to assess the value of delayed imaging after forced diuresis.
MATERIALS AND METHODS: Sixty-six patients underwent 68Ga-PSMA I&T PET/CT for evaluation of prostate cancer at 60 min post-injection. In subgroups of patients, this was amended by delayed imaging after 180 min post-injection, preceded by furosemide and oral hydration early, at the time of tracer injection, or delayed, at 100 min post-injection. Urinary tracer activity within the bladder and focal ureteral activity was analyzed.
RESULTS: After forced diuresis, linear and focal visualization of ureters was significantly reduced. After delayed furosemide, mean and peak bladder activity decreased (p < 0.001), and image quality of the prostate region improved on delayed images (p < 0.001). Early furosemide co-injection with tracer resulted in increased mean and peak bladder activity (p < 0.001) and in deteriorated image quality of the prostate region on delayed images (p = 0.008).
CONCLUSION: Ga-PSMA I&amp;T PET/CT delayed imaging after forced diuresis can improve the assessment of prostate region and pelvic lymph nodes by removing excreted tracer from the lower urinary tract. KEY POINTS: • Forced diuresis can improve image quality in 68 Ga-PSMA I&amp;T. • After forced diuresis, linear and focal visualization of ureters was reduced. • Timing of diuresis relative to 68 Ga-PSMA I&amp;T injection is important. • Early furosemide co-injection with tracer resulted in deteriorated image quality on delayed images. • After delayed furosemide, image quality improved on delayed images.

Entities:  

Keywords:  Dual time-point; Forced dieresis; Furosemide; PET/CT; PSMA

Mesh:

Substances:

Year:  2016        PMID: 27011373     DOI: 10.1007/s00330-016-4308-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  20 in total

1.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

2.  Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors.

Authors:  Koichi Koyama; Terue Okamura; Joji Kawabe; Nozomi Ozawa; Kenzi Torii; Naohiko Umesaki; Masato Miyama; Hironobu Ochi; Ryusaku Yamada
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

3.  Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.

Authors:  Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

4.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

Authors:  Martina Benešová; Martin Schäfer; Ulrike Bauder-Wüst; Ali Afshar-Oromieh; Clemens Kratochwil; Walter Mier; Uwe Haberkorn; Klaus Kopka; Matthias Eder
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

5.  Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies.

Authors:  Ehab M Kamel; Patrice Jichlinski; John O Prior; Jean-Yves Meuwly; Jean-Francois Delaloye; Laurent Vaucher; Jerome Malterre; Sandra Castaldo; Hans-Juerg Leisinger; Angelika Bischof Delaloye
Journal:  J Nucl Med       Date:  2006-11       Impact factor: 10.057

6.  Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.

Authors:  Steve Y Cho; Kenneth L Gage; Ronnie C Mease; Srinivasan Senthamizhchelvan; Daniel P Holt; Akimosa Jeffrey-Kwanisai; Christopher J Endres; Robert F Dannals; George Sgouros; Martin Lodge; Mario A Eisenberger; Ronald Rodriguez; Michael A Carducci; Camilo Rojas; Barbara S Slusher; Alan P Kozikowski; Martin G Pomper
Journal:  J Nucl Med       Date:  2012-12       Impact factor: 10.057

7.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

8.  Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.

Authors:  Tobias Maurer; Gregor Weirich; Margret Schottelius; Martina Weineisen; Benjamin Frisch; Asli Okur; Hubert Kübler; Mark Thalgott; Nassir Navab; Markus Schwaiger; Hans-Jürgen Wester; Jürgen E Gschwend; Matthias Eiber
Journal:  Eur Urol       Date:  2015-05-06       Impact factor: 20.096

9.  Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.

Authors:  Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

10.  Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.

Authors:  Martina Weineisen; Jakub Simecek; Margret Schottelius; Markus Schwaiger; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2014-11-25       Impact factor: 3.138

View more
  36 in total

1.  PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.

Authors:  Thorsten Derlin; Sebastian Schmuck; Cathleen Juhl; Johanna Zörgiebel; Sophie M Schneefeld; Almut C A Walte; Katja Hueper; Christoph A von Klot; Christoph Henkenberens; Hans Christiansen; James T Thackeray; Tobias L Ross; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-07       Impact factor: 9.236

2.  68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Authors:  Christos Sachpekidis; Leyun Pan; Boris A Hadaschik; Klaus Kopka; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

3.  Inguino-scrotal bladder hernia: an unexpected finding on 68Ga-PSMA-11 PET/CT.

Authors:  Shirin Shahlaei; Sara Shakeri; Fatemeh Farahmandfar; Farshad Emami; Ramin Sadeghi
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

4.  Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.

Authors:  Christoph Berliner; Milena Tienken; Thorsten Frenzel; Yuske Kobayashi; Annabelle Helberg; Uve Kirchner; Susanne Klutmann; Dirk Beyersdorff; Lars Budäus; Hans-Jürgen Wester; Janos Mester; Peter Bannas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-28       Impact factor: 9.236

5.  Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients.

Authors:  Christian Uprimny; Steffen Bayerschmidt; Alexander Stephan Kroiss; Josef Fritz; Bernhard Nilica; Anna Svirydenka; Clemens Decristoforo; Gianpaolo di Santo; Elisabeth von Guggenberg; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-08       Impact factor: 9.236

6.  Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.

Authors:  Sebastian Schmuck; Stefan Nordlohne; Christoph-A von Klot; Christoph Henkenberens; Jan M Sohns; Hans Christiansen; Hans-Jürgen Wester; Tobias L Ross; Frank M Bengel; Thorsten Derlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-09       Impact factor: 9.236

7.  Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy.

Authors:  Benedikt Kranzbühler; Hannes Nagel; Anton S Becker; Julian Müller; Martin Huellner; Paul Stolzmann; Urs Muehlematter; Matthias Guckenberger; Philipp A Kaufmann; Daniel Eberli; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-14       Impact factor: 9.236

8.  Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer.

Authors:  Daniel Walacides; Astrid Meier; Anne Caroline Knöchelmann; Daniele Meinecke; Thorsten Derlin; Frank M Bengel; Tobias L Ross; Hans-Jürgen Wester; Katja Derlin; Markus A Kuczyk; Christoph A J von Klot; Hans Christiansen; Christoph Henkenberens
Journal:  Strahlenther Onkol       Date:  2019-01-04       Impact factor: 3.621

9.  64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer.

Authors:  Teli Liu; Chen Liu; Zhongyi Zhang; Ning Zhang; Xiaoyi Guo; Lei Xia; Jinquan Jiang; Qing Xie; Kun Yan; Steven P Rowe; Hua Zhu; Zhi Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-25       Impact factor: 9.236

10.  Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation.

Authors:  Evyn G Arnfield; Paul A Thomas; Matthew J Roberts; Anita M Pelecanos; Stuart C Ramsay; Charles Y Lin; Melissa J Latter; Peter L Garcia; David A Pattison
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.